When did REGN join the S&P 500?

Regeneron Pharmaceuticals joined the S&P 500 index on 2013-04-30.

What sector is REGN in?

REGN is in the Health Care sector, Biotechnology industry.

REGN — Regeneron Pharmaceuticals

Name: REGN Institutional Holdings (13F) — 2026Q1
Creator: SEC EDGAR
License: https://www.sec.gov/data

Biotechnology · Health Care

S&P 500 Timeline

2013-04-30Joined S&P 500

Regeneron Pharmaceuticals is a biotechnology company engaged in the discovery, invention, development, manufacturing, and commercialization of drugs. Its product portfolio includes EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company accelerates drug development through its proprietary VelociSuite technologies, including VelocImmune, which uses uniquely genetically humanized mice to produce optimized fully human and bispecific antibodies.

Key Facts

Status	Active
Sector	Health Care
Industry	Biotechnology
Joined	2013-04-30
Tenure	13 yrs

Industry Peers

ABBV AMGN BIIB GILD INCY MRNA VRTX

Sector Peers

A ABBV ABT ALGN AMGN BAX BDX BIIB BMY BSX

Institutional Holdings (13F)

1,399 institutions hold REGN, totaling 106.6M shares ($78.9B) · As of 2026Q1

Rank	Institution	Shares	Value
1	VANGUARD CAPITAL MANAGEMENT LLC	13.3M	$10.3B
2	BlackRock, Inc.	8.9M	$6.9B
3	STATE STREET CORP	4.7M	$3.6B
4	BARCLAYS PLC	4.1M	$3.5B
5	Dodge & Cox	4.5M	$3.4B
6	JPMORGAN CHASE & CO	4.3M	$3.2B
7	MORGAN STANLEY	4.2M	$2.9B
8	FRANKLIN RESOURCES INC	2.7M	$2.1B
9	GEODE CAPITAL MANAGEMENT, LLC	2.6M	$2.0B
10	GOLDMAN SACHS GROUP INC	2.4M	$1.9B

View all holders →

Data source: Wikipedia · CC BY-SA 4.0 · SEC EDGAR 13F · Updated 2026-07-10